http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
-
Aristotle (ARTL) Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
-
Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
-
Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
-
Aristotle (ARTL) Receives $3.0 Million in Net Proceeds from Exercise of Warrants
-
Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
-
Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
-
Artelo Biosciences to Present at the LSX World Congress Virtual Conference
-
Artelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update
-
Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference
-
Artelo Biosciences Files Patent Application for New Formulation of ART27.13
-
Artelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th
-
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
-
Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs
-
Aristotle (ARTL) Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
-
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
-
Artelo Biosciences to Present at the Virtual Fall Investor Summit on November 18th
-
Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update
-
Aristotle (ARTL) Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
-
Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
-
Aristotle (ARTL) Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for Treatment of Cancer-Related Anorexia
-
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia
-
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
-
Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
-
Artelo Biosciences to Present at The LD 500 Virtual Investor Conference on September 1st
-
Artelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
-
Aristotle (ARTL) Announces Expanded Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
-
Artelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
-
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
-
Artelo Biosciences (ARTL) Awarded Composition of Matter Patent for Novel CBD Cocrystal
-
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
-
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
-
Artelo Biosciences to Present at the Spring Investor Summit on March 25th
-
Artelo Biosciences to Present at the Spring Investor Summit on March 25th
-
Artelo Biosciences to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
-
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
-
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
-
Artelo Biosciences to Present at the LSX World Congress in London
-
Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update
-
Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors
-
Artelo Biosciences to Present at the 12th Annual LD Micro Main Event
-
Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
-
Aristotle (ARTL) Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
-
Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
-
Artelo Biosciences to Present at the Annual Investival Showcase in London
-
Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13
-
Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
-
Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine
-
Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th
-
Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
